Top Health Tech Companies in Dublin (89)
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.
Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.
Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.
Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.
Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.
Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in...
Ipsen's Top Stability & Growth Strengths
Strong Revenue Growth: Reported results show double-digit growth at constant exchange rates in 2024 and 2025 with an accelerated start in Q1 2026, and guidance indicates continued expansion in 2026. This momentum spans all three therapeutic areas rather than a single product.
Profitability: Disclosures highlight expanding core operating margins above the mid-30s and rising core operating income. Guidance continues to target strong margins alongside growth.
Diversified Revenue Streams: Recent updates indicate contributions from Oncology, Rare Disease, and Neuroscience, with products excluding Somatuline growing strongly and rare disease accelerating. Strategic acquisitions and partnerships have broadened the base beyond any single legacy brand.
FDB (First Databank) creates and delivers the world’s most powerful drug knowledge that ignites, inspires, and illuminates critical medication decisions. We collaborate with our partners to help improve patient safety, operational efficiency, and health outcomes. Our drug databases drive healthcare information systems that serve the majority of hospitals, physician practices, pharmacies, payers, and all other areas of healthcare and are...
Eirdoc Online Doctor: Your Convenient Gateway to Quality Healthcare. Experience the ease and accessibility of online healthcare with Eirdoc Online Doctor. Our team of experienced and qualified physicians is available to provide immediate GP consultations via video or telephone, ensuring that your health remains a top priority without disrupting your busy schedule.
Axios International is a leading healthcare access company that has worked since 1997 to transform access to healthcare by putting quality care and treatment within reach. With over 28 years of experience, they design and implement effective and sustainable solutions to patient access challenges in emerging markets, serving nearly 10 million people across more than 100 countries to ensure all...
A public company, founded over 25 years ago, Consensus is the global leader in digital cloud and fax technology. Focusing in the healthcare space, we use interoperability to unify multiple systems that wouldn’t otherwise talk to each other. With exciting new initiatives on the horizon, we are continuing our strategic expansion. Read on to learn why now is the ideal...
Consensus Cloud Solutions's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst recognition placed the company among the Leaders in worldwide digital fax, supporting a top-tier position in its core niche. Long tenure and scale around the eFax franchise plus regulated-workflow add-ons reinforce defensibility in compliance-heavy document exchange.
Healthy Cash Flow: Free cash flow increased to a record level in 2025, indicating strong cash generation even amid mixed topline performance. Operating cash flow also rose, providing flexibility to fund strategy and capital allocation.
Profitability: Adjusted EBITDA remained very high with margins around the low-50% range, signaling durable profitability. Guidance also points to continued strong earnings power alongside modest revenue growth expectations.
Using the latest technology Allview Healthcare gives you access to leading Consultant Dermatologist and surgical services Rapid diagnosis and results within weeks Specialising in Skin Cancers, Moles, Rash, Acne and Lesions
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of...
Bristol Myers Squibb's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests BMS holds a top‑tier global position with anchor franchises like Eliquis and Opdivo and a broad oncology footprint including cell therapies, reinforcing sustained competitive advantage.
Product Line Growth: Feedback suggests the company’s “growth portfolio” of newer medicines is expanding strongly, with assets such as Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy helping to offset legacy declines.
Future-Ready Strategy: Feedback suggests recent acquisitions and collaborations (Karuna/Cobenfy, RayzeBio, Mirati, BioNTech) broaden modalities and late‑decade growth drivers, positioning the company to sustain leadership beyond current headwinds.
seamlessCARE Ltd. develops innovative assistive technologies that are grounded in years of health care, industry and academic research. Empathic app and API interprets the emotions of non-verbal people. This is the first of many technologies to enhance the lives of adults and children with complex needs.
Glanbia Nutritionals is a nutrition solutions partner that helps deliver better nutrition in foods, beverages, and supplements through innovative ingredients and product development support.
The Wellola team believes only the sickest of the sick should be hospitalised and that the future of healthcare is preventative, community-based and supported by digital tools. Wellola prides itself in being highly user-focused, reliable, robust and easy-to-use. Our team have unique, in-depth sector know-how, our pricing model is extremely cost effective and our business model is scalable for national...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
At Fitbit, we created an entire industry around wearable technology with software and services to help people transform their lives for the better, from the smallest milestones to the biggest changes. 10k steps started out as a magic number and became an anthem for setting goals—but today, we take the Fitbit community well beyond it. Our global teams are on...
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Medtronic is a global healthcare solutions company operating in approximately 160 countries. We are committed to improving lives through our medical technologies, services, and solutions. Since our beginning, 60 years ago, our Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. The Mission is our ethical framework and inspirational goal guiding...
Medtronic's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue accelerated to the fastest annual pace in a decade in FY2026, with momentum evident into the fourth quarter. Management’s outlook points to continued upper single‑digit organic expansion in the coming year.
Healthy Cash Flow: Strong free cash flow and a long-running pattern of dividend increases indicate durable cash generation. Recent dividend actions and ongoing cash returns underscore capacity to fund investment and tuck‑in M&A.
Strong Market Position & Advantage: Scale leadership at the top of global medtech by revenue, with breadth across Cardiovascular, Neuroscience, and Medical Surgical, supports resilience. Category strength in areas like cardiac pacing and ablation provides commercial leverage for new launches.
The Avoca Clinic is Ireland’s leading Plastic Surgery Clinic for a reason. Located in multiple discrete locations around the country, you’ll immediately feel the warmth and luxury of our beautifully designed spaces that are home to some of the most technologically advanced equipment and world-class surgeons. Offering the very latest procedures and techniques available to the cosmetic surgery industry, we...
At ABC Fitness, we're passionate about fitness. We believe that everyone deserves the opportunity to be their best selves and live their best lives. Our technology solutions are designed to empower fitness businesses and individuals to achieve their goals, whether it's building a stronger community, streamlining operations, or providing personalized training experiences. We're committed to making fitness accessible and enjoyable...
ABC Fitness Solutions's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests ABC holds a leading position for enterprise gyms and payments at scale, reinforced by multi-platform coverage across operators. External mentions of leadership and large-scale operations indicate durable competitive presence in core segments.
Market Expansion: Feedback suggests ABC has expanded globally with usage in over 100 countries and strengthened regional presence in Latin America via EVO. Partnerships with major franchises and international brands further extend its footprint.
Innovation-Driven Growth: Feedback suggests ongoing product innovation—AI-powered operating infrastructure, new CRM/BI releases, and deeper cross-product integrations—is propelling growth. Regular launches across Ignite, Glofox, Trainerize, and EVO point to a forward-leaning roadmap.
BVI® is refocusing the future of vision. As one of the fastest-growing, diversified surgical ophthalmic businesses in the world, our purpose-built portfolio of trusted brands includes: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs), and spans more than 90 countries. We’ve set our sights on touching the lives of millions of patients affected...
